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Abstract: Molecular-dynamics simulations with metadynamics 
enhanced sampling reveal three distinct binding sites for arginine 
vasopressin (AVP) within its V2-receptor (V2R). Two of these, the 
vestibule and intermediate sites, block (antagonize) the receptor 
and the third is the orthosteric activation (agonist) site. The contacts 
found for the orthosteric site satisfy all the requirements deduced 
from mutagenesis experiments. Metadynamics simulations for V2R 
and its V1aR-analog give an excellent correlation with experimental 
binding free energies by assuming that the most stable binding site 
in the simulations corresponds to the experimental binding free 
energy in each case. The resulting three-site mechanism separates 
agonists from antagonists and explains subtype selectivity. 
G-protein coupled receptors (GPCRs) represent one of nature’s 
most successful designs. They not only control many biological 
processes but are also remarkably versatile. One receptor can 
exert control mechanisms via one or more G-proteins and/or the 
arrestin pathway. These pathways involve intracellular binding 
partners that have been shown[1] to affect ligand binding in 
accord with the ternary-complex model.[2] GPCR ligands are 
also diverse in function; they may be agonists, antagonists, 
inverse or partial agonists and act differently on the alternative 
pathways (biased agonists). They account for approximately 
40% of all marketed drugs.[3] Much remains unknown about the 
mechanisms for these diverse functions. Even though high-
resolution crystal structures have contributed substantially to 
clarifying the structure and function of GPCRs, they capture only 
static snapshots that occur within very complex molecular 
mechanisms. Molecular-dynamics (MD) simulations represent 
one of the few possibilities to extend the information provided by 
crystallographic structures to reveal the atomistic details of 
GPCR-activation.[4] 
The vasopressin receptors are GPCR drug targets, in particular 
for antidiuresis and vasopression.[5] Their natural ligand in 
mammals is arginine vasopressin (AVP, Cys-Tyr-Phe-Gln-Asn-
Cys-Pro-Arg-Gly-NH2). AVP is closely related to the non-
mammalian lysine-vasopressin, oxytocin and urotensin, which all 
exhibit six-residue rings closed by a disulfide bond. The ring can 
exhibit different conformations, both in different crystal 
structures[6] and solution.[7]  
Three different AVP-receptor-subtypes are known: V1aR, V1bR 
and V2.[8] V2R is localized in the renal collecting duct[9] and 
associated with nephrogenic diabetes insipidus (NDI).[10] Only 
two non-peptide ligands for this target, the V2R/V1aR-antagonist 
conivaptan 1 and the V2R-antagonist tolvaptan 2 (Scheme 1) 
have received FDA approval, although the selective V2R-agonist 
peptide desmopressin remains the drug of choice for NDI. [11]  
No crystal structures are available for the vasopressin-receptors 
but abundant mutagenesis data exist.[8a] The N-terminus and 
first extracellular loop (ECL1) of V1aR are essential for ligand 
binding. The hydrophilic residues Gln1082.61, Lys1283.29, 
Gln1313.32 and Gln1854.60 in V1aR contribute to both AVP binding 
and its ability to activate vasopressin receptors.[12] No binding 
Scheme 1. Conivaptan 1, Tolvaptan 2, Lixivaptan 3, Satavaptan 
4 and MCF18, 5. 
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pose that satisfies all these contacts has been proposed for AVP 
in its receptors. 
We now report a computational study of the AVP/V2R system. It 
not only reveals a binding pose compatible with all the V1aR 
mutation data and a quantitative model for ligand binding in V1aR 
and V2R but also proposes a new mechanism for the modes of 
action of different ligand types. 
A homology model (see the Supporting Materials, SM) was 
refined using a 1 µs MD-simulation, above all to equilibrate the 
loops and the modeled N-terminus. This subdomain folded to 
form hydrogen bonds with the receptor surface and remained 
stable for the last 900 ns of the simulation. Although we cannot 
be sure, the simulation suggests that the receptor has reached a 
stable conformation. The N-terminal insertion quickly adopted a 
conformation resembling those of the neurotensin 1 and µ-opioid 
receptors,[1c,13] (see Fig. S1 of the SM). Otherwise, the 
simulation changed little from the homology model.  
Two 6.5 µs MD-simulations in which two AVP molecules were 
initially placed in the extracellular solvent above the receptor 
surface were performed. One resulted in an AVP molecule 
docking into a vestibule complex that remains stable for the final 
six µs of the simulation (Fig. 1). These simulations indicate an 
energy barrier between the vestibule complex and deeper 
binding pockets. This barrier was first reported by Dror et al. 
using unbiased MD simulations on the β2-adrenergic receptor[14] 
and extended to the muscarinic M2 and M3 receptors using both 
unbiased[15] and accelerated MD (enhanced sampling).[16] The 
ligand paused in a vestibule position (between ECL2 and ECL3) 
before moving into multiple deeper binding sites, including 
intermediate and orthosteric sites.[14,17] However, the magnitude 
of the barriers between the sites and their relative free-energy 
differences were not quantified. Vestibule complexes have been 
found, for instance, for the muscarinic M2[18] and M3[15] receptors 
and the extracellular loops are known to play important roles in 
the biology of GPCRs.[19] As these simulations suggested the 
existence of at least two binding sites (vestibule and orthosteric), 
we investigated the binding path using metadynamics 
simulations.  
Adaptive biasing force simulations[20] provided an initial guess for 
possible binding pathways for metadynamics simulations on the 
binary AVP-V2R complex (see the SM and Fig. S2 for details). 
We used a combination of funnel metadynamics[21] in its well-
tempered variant[22] and a path collective variable (PCV),[23] a 
combination that has proven to be very effective for investigating 
protein-ligand interactions.[20,24] Three walkers were placed along 
the path using the multiple walker technique.[25] Fig. 2 shows a 
projection of the free-energy landscape onto the path variables 
and the main minima and barriers involved in binding. The 
simulation converged after more than 3.9 µs to reveal three 
energy minima (see Fig. S3) that correspond to:  
1. The vestibule complex (binding free energy, calculated ΔGB = 
−11.6 kcal mol-1),  
2. An intermediate binding site (calculated ΔGB = -10.3 kcal 
mol−1) separated by a low barrier from the vestibule binding site 
and a higher one (calculated barrier 15 kcal mol−1) from the 
orthosteric site, and  
3. An orthosteric-binding site that satisfies all interactions 
required by the mutagenesis studies for AVP to interact and 
activate the vasopressin receptors. This site is the most stable of 
the three with a calculated ΔGB of −12.6 kcal mol-1 (experimental 
Ki=0.78 nM = −12.9 kcal mol-1). Figure S3 of the SM shows the 
contacts between ligand and receptor found for these three 
complexes.  
Fig. 1. A representative average structure of the stable AVP-V2R extracellular vestibule complex obtained from the unbiased 6.5 µs 
MD simulation. 
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The calculated ΔGB is most negative for the orthosteric site and 
agrees very well with experiment. However, both the vestibule 
and intermediate sites correspond to metastable minima in the 
free energy landscape and might be druggable. The large barrier 
between the intermediate and orthosteric sites (the “activation 
barrier”) strongly suggests a cooperative mechanism between 
the G-protein (or β-arrestin) and a ligand for receptor activation. 
We hypothesize that ligand binding in the intermediate site of the 
receptor in the absence of an intracellular protein binding partner 
cannot lead to activation because the intermediate site blocks 
the orthosteric one, which is known[2] to lead to activation (black 
profile in Fig. 2B). Furthermore, a plausible cooperative 
activation mechanism is that the activation barrier is lower in the 
ternary complex than in the binary one, so that the orthosteric 
site can be populated in the presence of the G-protein and 
receptor activation can occur. This hypothetical barrier lowering 
(blue profile in Fig. 2B) results from the extra stabilization of the 
ligand binding to the orthosteric site, as proposed by the ternary 
complex model.[1,20] In the ternary complex model, the ligand and 
the G-protein cooperate to reinforce binding to the orthosteric 
site. This stabilization should also result in a lowering of the 
activation barrier, as indicated in Figure 2B. 
In order to test this interpretation, we simulated four non-peptide 
ligands to investigate the subtype and functional selectivity 
toward V1aR and V2R. The V2R structure after 7.5 µs MD 
simulation was used as a template to construct a model for V1aR, 
which was then refined by 0.5 µs of MD simulation. The ligands 
were a non-selective V2/V1a antagonist 1,[26] a selective V2 
antagonist 3,[27] a functionally selective V2 modulator (Gs 
antagonist/arrestin partial agonist) 4[28] and a functionally 
selective V2 modulator (Gs agonist) 5.[29] The experimental free 
binding energies were derived from the corresponding binding 
constants, which are shown in Table 1.  
The free-energy profiles obtained from metadynamics 
simulations (Fig. 3) all indicate that V2R always favors the 
vestibule, and V1aR the intermediate site. Note that the three-site 
model leads to the unusual prediction that competitive 
antagonists need not bind to the same site as the agonists that 
they displace. This is because ligands in both the vestibule and 
the intermediate sites block access to the orthosteric site so that, 
once it has left the receptor, an agonist can no longer bind in the 
presence of an antagonist in one of the non-activating sites. It is 
known[30] that the important residues for non-peptide antagonist 
binding to V1aR are different to those involved in agonist 
binding.[31] 
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Figure 2. A) The free energy hypersurface obtained from the metadynamics simulation using the path PCV as a function of the 
progression on the path s(R) (a dimensionless number representing the relative position on the path) and the distance from the 
path s(Z) in nm (see the SM for more information). B) A schematic diagram of the energy levels found for AVP bound to V2R. The 
dotted arrows give energy differences (binding free en rgies or free energies of activ tion) in kcal mol-1. The blue arrows and 
energy levels show the hypothetical effect of binding a G-protein or β-arrestin. The experimental binding free energy is shown in 
parentheses. 
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Table 1. Binding affinities (Ki in nM) of the non-peptide ligands used in this study, the experimental free energy of binding, ΔGB is 
calculated using ∆GB=−RT ln(Ki) (T = 298K) and the calculated one is taken from the depths of the corresponding minima in the 
metadynamics profiles shown in Figure 3 (both in kcal mol-1). The assignments of the binding sites refer to the simulations and 
errors to the funnel sampling next to the global minima according to the scheme reported by Saladino et al.[32] The underlined 
simulation data are used in the correlation shown in Figure 4. 
Ligand Effect V1aR  V2R Site Experiment Simulation  Site Experiment Simulation 
   Ki ΔGB ΔGB   Ki ΔGB ΔGB 
Conivaptan, 1[26] Non-selective antagonist Intermediate 0.43 -13.0 -11.5 ± 0.9  Vestibule 0.36 -12.9 -11.4 ± 0.5 
Lixivaptan, 3[27] Selective V2-antagonist Intermediate 44 -10.1 -9.5 ± 1.7  Vestibule 2.3 -11.9 -10.7 ± 0.2 
Satavaptan, 4[28] Selective V2-biased 
selective Gα-antagonist 
and partial arrestin 
agonist 
Orthosteric 460 -8.7 -9.1 ± 1.1  Vestibule 
0.54 -12.7 
-11.0 ± 0.7 
Intermediate -8.0 ± 1.1  
MCF18, 5[29] V2-Selective GS agonist Intermediate 106 -9.6 -9.1 ± 1.2  Orthosteric 
20 -10.5 
-10.1 ± 2.3 
 Vestibule -10.6 ± 2.3 
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Is the three-site model compatible with the known facts? Fig. 4 
shows a correlation of the experimental binding free energies 
against those found for the most stable binding site in Figures 
3A-D (the calculated ΔGB). This correlation is good (R2 = 0.93), 
even though it involves three different types of binding site. This 
agreement can be seen to support the three-site model. The 
simplest hypothesis is that any ligand that binds most strongly to 
the orthosteric binding site will be an agonist. Partial agonists 
most likely bind in equilibrium between the orthosteric and either 
the intermediate or vestibule sites. Antagonists may bind to 
either the vestibule or intermediate site (or both). The observed 
behavior of ligands 1, 3 and 4 is consistent with this picture. 
MCF18, 5, gives the least clear picture. It activates less strongly 
than AVP but binds only weakly, so that its experimental 
classification is ambiguous.  
The simulations have provided a wealth of information and a 
new hypothesis that explains many features of the complex 
interplay between GPCRs, their ligands and their intracellular 
binding partners. Previous free-energy perturbation simulations 
have been used successfully to predict relative binding-free-
energy differences (ΔΔG) between GPCR-ligands.[33] However, 
as far as we are aware, the current simulations are unique 
because they provide absolute binding energies with 
unprecedented accuracy, classify unknown ligands as agonists, 
antagonists or partial agonists and reveal unsuspected sources 
of subtype-specificity such as, for instance, the fact that 
antagonists bind to a different site (vestibule) in V2R than in V1aR 
(intermediate). It now remains to test this hypothesis for other 
GPCRs and to demonstrate that simulations can reproduce the 
effect of the intracellular binding partner on ligand binding and 
vice versa. Above all, however, this work has demonstrated the 
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Figure 3. Free-energy profiles from the metadynamics simulations of A) Conivaptan 1, B) Lixivaptan 3, C) Satavaptan 4 
and D) MCF18 5. The approximate value-ranges for the path coordinate for the three sites are: orthosteric 0.5-0.7 nm, 
intermediate 0.7-1.0 nm and vestibule 1.4-1.6 nm. However, the reaction coordinate does not distinguish well between 
orthosteric and intermediate around 0.7 nm, so that visual inspection and contacts to the receptor were also used to 
assign the sites (See Fig. S4). The simulation binding energies listed in Table 1 refer to the depths of the corresponding 
minima in these curves. The free energy scale is relative to the separated ligand and receptor. 
Figure 4. Correlation of the calculated and experimental free 
binding energies for four V1aR and V2R ligands (data from 
Table 1 and binding-site assignments from Fig. 3). The two 
open circles indicate less stable alternative binding sites for 
Satavaptan and MCF18 that are not included in the correlation. 
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power of modern hard- and software combinations in GPCR 
research.  
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